Filters:
Children with Brain Tumors Who Undergo Radiation Therapy Are Less Likely to Recall Recent Personal Events than to Remember Happenings from Before Treatment
Baylor University
Children with certain types of brain tumors who undergo radiation treatment are less likely to recall the specifics of events they experienced after radiation than to remember pre-treatment happenings, according to a study comparing them to children with healthy brains.
NYU Langone's Blood & Marrow Transplant Program Expands Services
NYU Langone Health
NYU Langone's Blood and Marrow Transplant Program expands services and receives accreditation for adult allogeneic transplants.
New Drug Could Prevent Debilitating Side Effect of Cancer Treatment
American Chemical Society (ACS)
About 50,000 people in the U.S. are diagnosed annually with head, neck, nasal and oral cancers. Most are treated with radiation, and of those, 70-80 percent develop a painful and debilitating side effect called severe oral mucositis (SOM).
Weaponizing Oxygen to Kill Infections and Disease
American Chemical Society (ACS)
The life-threatening bacteria called MRSA can cripple a hospital since it spreads quickly and is resistant to treatment. But scientists report that they are now making advances in a new technique that avoids antibiotics. Instead, they are using light to activate oxygen, which then wipes out antibiotic-resistant bacteria. The method also could be used to treat other microbial infections, and possibly even cancer.
Like Shark Attack and the Lottery, Unconscious Bias Influences Cancer Screening
University of Colorado Cancer Center
Doctors with personal experience of cancer are more likely to act against established guidelines to recommend that low-risk women receive ovarian cancer screening.
Blood Test Could Detect Kidney Cancer Up to Five Years Prior to Clinical Diagnosis
Beth Israel Deaconess Medical Center
A team of investigators led by Beth Israel Deaconess Medical Center (BIDMC) medical oncologist Rupal Bhatt, MD, PhD, has demonstrated that a molecule called KIM-1, a protein present in the blood of some patients with renal cell carcinoma is present at elevated levels at the time of diagnosis, can also serve as a tool to predict the disease's onset up to five years prior to diagnosis
Reaffirming its Role as a Statewide Resource, Rutgers Cancer Institute of New Jersey is Redesignated as the State's Only Comprehensive Cancer Center
Rutgers Cancer Institute of New Jersey
Rutgers Cancer Institute of New Jersey, the state's only Comprehensive Cancer Center as designated by the National Cancer Institute (NCI), has successfully renewed this designation.
Discovery May Help Provide Clues for Fighting and Treating HPV
Yale Cancer Center
Yale Cancer Center (YCC) scientists have filled in a key gap in understanding the unusual route by which the Human papillomavirus (HPV) infects cells.
PARP inhibitor improves progression-free survival in patients with advanced breast cancers and BRCA mutations
University of Texas M. D. Anderson Cancer Center
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
Fred Hutch Wins $1.26 Million Grant to Boost Science and Education Efforts
Fred Hutchinson Cancer Research Center
Fred Hutchinson Cancer Research Center announced it received a five year Science Education Partnership Award (SEPA) from The National Institute of General Medical Sciences (NIGMS), worth $1.26 million.
Penn Medicine's Carl June Receives 2018 Albany Prize
Perelman School of Medicine at the University of Pennsylvania
Carl June, MD, a gene therapy pioneer at the Abramson Cancer Center of the University of Pennsylvania, will receive the 2018 Albany Medical Center Prize in Medicine and Biomedical Research.
Byproducts of 'Junk DNA' Implicated in Cancer Spread
University of California San Diego
Biologists have revealed that enhancer RNAs play a significant role in cancer dissemination. The researchers found that eRNAs have a direct role in the activation of genes that are important for tumor development. This role is facilitated by the ability of eRNAs to directly interact with BRD4, a protein known as a cancer disseminator.
Removing the Most Common p53 Mutation in Colorectal Cancer Halts Disease Progression
Stony Brook University
By genetically manipulating and removing the most common mutant form of the p53 gene that promotes colorectal cancer in humans, an international team of scientists demonstrated that this therapy reduces tumor growth and tissue invasion.
Study Seeks Path for Drugs to Reach Brain Tumors
University of Maryland, Baltimore
The blood-brain barrier is a specialized network of vascular and brain cells that acts as the brain's security system, helping to safeguard the brain and regulate the flow of substances into and out of it.
Research Shows Surprising Scale of Health Benefits for Biggest Losers
University of Texas Health Science Center at Houston
When it comes to shedding pounds, it pays to think big, according to new research by The University of Texas Health Science Center at Houston (UTHealth).
Better Doctor/Patient Communication Means Better Outcomes in Cancer Care, According to a Report in JNCCN
National Comprehensive Cancer Network(r) (NCCN(r))
Study from the American Cancer Society, published in JNCCN--Journal of the National Comprehensive Cancer Network, found cancer patients who were more satisfied with the communication they received, had better health results at lower costs
Research Grant to Study Common Resistance to Papillary Thyroid Cancer Treatment Is Awarded to Ann-Kathrin Eisfeld, MD, by the American Thyroid Association
American Thyroid Association
The American Thyroid Association has awarded a 2018 Research Grant to Ann-Kathrin Eisfeld, MD, Clinical Fellow in Internal Medicine at Ohio State University. The topic of Dr. Eisfeld's project is "Novel NRAS isoform mediates BRAF-inhibitor resistance in papillary thyroid cancer--thinking outside the box to overcome 'inevitable' treatment failure." Papillary thyroid cancer (PTC) is one of the 10 most common malignancies in the United States, with almost 60,000 new people diagnosed each year. While almost all patients initially respond well to the current standard treatment with radioactive iodine, almost half of them will eventually develop resistance. Therapies that can provide additional treatment options for those patients are greatly needed.
Research Grant to Determine the Genes Responsible for Survival and Growth of Medullary Thyroid Cancer Is Awarded to Wayne Miles, PhD, by the American Thyroid Association
American Thyroid Association
The American Thyroid Association has awarded a 2018 Research Grant to Wayne Miles, PhD, Assistant Professor of Molecular Genetics at the Ohio State University. Dr. Miles's research project is entitled "Proteomic-led discovery of essential genes in Medullary Thyroid Cancer." Medullary thyroid cancer (MTC) is caused by the malignant growth of C-cells. Although MTC represents only a small fraction (2(break)4%) of all thyroid cancer cases and overall survival rates from MTC are good, patients diagnosed with advanced disease have poor five-year survival rates (28%). The genetic aberrations of the cancer result in C-cells receiving a continuous signal to grow and proliferate. To sustain their elevated growth rates, MTC cells adapt their genome (DNA), transcriptome (RNA), and proteome (the entire set of proteins expressed by a cell, tissue, or organism).
Keck Medicine of USC Ranks Highest in Southern California for Cancer Care
Keck Medicine of USC
Keck Medicine of USC leads as Southern California's highest-ranked cancer care provider, with cancer mortality rates that are the second-lowest in the nation, according to U.S. News & World Report's Best Hospitals report.
U.S. News & World Report Ranks Cedars-Sinai Among Top 10 Hospitals
Cedars-Sinai
Cedars-Sinai Medical Center been recognized by U.S. News & World Report's "Best Hospitals 2018-19" as one of the 10 best hospitals in the nation. The medical center ranked No. 8 in a select group of 20 Honor Roll hospitals and also had 12 medical specialties ranked nationally in the magazine's latest hospitals rankings released Tuesday.
Keck Medicine of USC Hospitals Ranked Among the Country's Best for 10th Year in a Row
Keck Medicine of USC
U.S. News & World Report's 2018-2019 Best Hospitals rankings place Keck Medicine of USC hospitals among the top 50 nationwide in nine specialties, the top three in Los Angeles and the top seven in California.
NDSU Research Foundation and OncoThira Announce License Agreement to Develop & Market Compounds Discovered at NDSU for the Treatment of Cancer
North Dakota State University
OncoThira will develop and market compounds discovered by NDSU pharmaceutical sciences researcher Steven Qian that take advantage of high COX-2 expression in cancer to down regulate cancer promoting prostaglandins and elevate production of the recently characterized anti-cancer compound 8-HOA
AACI Members Choose Knudsen President-Elect, Four Added to Board of Directors
Association of American Cancer Institutes (AACI)
The members of the Association of American Cancer Institutes (AACI) have elected Karen E. Knudsen, PhD, as vice president/president-elect of AACI's board of directors. In addition to Dr. Knudsen, four leaders of AACI member cancer centers will join the board at the AACI/CCAF Annual Meeting on September 30.
Research Grant to Determine How Specific Drugs Work or Fail in Anaplastic Thyroid Cancer Is Awarded to Miles Miller, PhD, by the American Thyroid Association
American Thyroid Association
The American Thyroid Association has awarded a 2018 Research Grant to Miles Miller, PhD, principal investigator at the Massachusetts General Hospital Center for Systems Biology and Assistant Professor of Radiology at Harvard Medical School. Dr. Miller's research project is titled "Co-opting tumor-associated macrophages in anaplastic thyroid cancer to enhance immune-checkpoint blockade response." Treatment of advanced metastatic cancer has seen a revolution over the last several years, as new therapeutic strategies have become successful at harnessing the power of the immune system to durably attack malignant and mutated cancer cells. Immune-checkpoint blockade therapies targeting programmed-death 1 (PD1) signaling on T-cells have been successful in the treatment of solid cancers, including heavily mutated melanomas and lung cancers. Unfortunately, these treatments only work in a fraction of patients, and resistance is often associated with the presence of a type of tumor-promoting imm
Doctor-Patient Discussions Neglect Potential Harms of Lung Cancer Screening, Study Finds
University of North Carolina Health Care System
Although national guidelines advise doctors to discuss the benefits and harms of lung cancer screening with high-risk patients because of a high rate of false positives and other factors, those conversations aren't happening the way they should be, according to a study by researchers from the University of North Carolina Lineberger Comprehensive Cancer Center.
Duke Team Finds Missing Immune Cells That Could Fight Lethal Brain Tumors
Duke Health
Researchers at Duke Cancer Institute have tracked the missing T-cells in glioblastoma patients. They found them in abundance in the bone marrow, locked away and unable to function because of a process the brain stimulates in response to glioblastoma, to other tumors that metastasize in the brain and even to injury.
Research Grant for Study of Resistance to Precision Medication for Medullary Thyroid Cancer Is Awarded to Brendan Frett, PhD, by the American Thyroid Association
American Thyroid Association
The American Thyroid Association has awarded a 2018 Research Grant to Brendan Frett, PhD, Assistant Professor in the College of Pharmacy at the University of Arkansas for Medical Sciences. The title of Dr. Frett's project is "Dual Inhibition of RET and Aurora B to Study the Simultaneous Regulation of Multiple Oncogene Pathways in Medullary Thyroid Cancer." Since its inception in 1971, the War on Cancer has resulted in significant treatment breakthroughs. One of the most important was the discovery of cancer-promoting oncogenes (genes with the potential to cause cancer). Researchers theorized that oncogenes could be strategically targeted while sparing normal cells, which sparked the era of precision medicine for oncology. Early medicine discoveries were quickly followed by the realization that secondary mutations in cancers often resulted in resistance to the drugs and relapse of the disease. This was solved by generating inhibitors that achieved activity on multiple forms of the onc
$1M Commitment from Embrace Kids Foundation Supports Recruitment of Pediatric Cancer Research Faculty at Rutgers Cancer Institute of New Jersey
Rutgers Cancer Institute of New Jersey
Rutgers Cancer Institute of New Jersey now has additional resources in the fight against pediatric cancers and blood disorders, thanks to a $1 million commitment from Embrace Kids Foundation that will support the recruitment of pediatric cancer research faculty.
For the 50 Million
American Autoimmune Related Diseases Association (AARDA)
7th DC Metro Autoimmune Walk -- Linking Together for a Cure
Scientists Uncover New Details in How Sense of Smell Develops
Washington University in St. Louis
Researchers at Washington University School of Medicine in St. Louis have uncovered new details in how the olfactory epithelium develops. The new knowledge could help scientists prove that turbinates and the resulting larger surface area of the olfactory epithelium are one definitive reason dogs smell so well.
Late effects of treatment hinder independence of adult survivors of childhood brain tumors
St. Jude Children's Research Hospital
In the first study of its kind, St. Jude Children's Research Hospital investigators have found that more than half of pediatric central nervous system tumor survivors do not achieve complete independence as adults. Researchers looked at six aspects of independence in more than 300 survivors, including employment, independent living, marital status, assistance with routine or personal care needs, and the ability to drive.
Nuclear Gatekeeper Could Block Undruggable Prostate Cancer Targets
Thomas Jefferson University
Blocking nuclear gateways that traffic cancer-promoting molecules to nucleus, could offer a new way to target aggressive cancer.
Drugs in Development for Cancer May Also Fight Brain Diseases, including ALS
Perelman School of Medicine at the University of Pennsylvania
A class of cancer drugs called PARP inhibitors could be useful for treating and preventing brain disorders, including ALS (Lou Gehrig's disease) and some forms of frontotemporal degeneration, by halting the misplacement of specific proteins that affect nerve cells.
An Ancient Medicine Shows New Promise: Arsenic in Combination with an Existing Drug Could Combat Cancer
Beth Israel Deaconess Medical Center
Investigators have discovered that arsenic in combination with an existing leukemia drug work together to target a master cancer regulator. The team, led by researchers at the Cancer Center at Beth Israel Deaconess Medical Center, is hopeful that the discovery could lead to new treatment strategies for diverse types of cancer.
Cancer Cells Send Out "Drones" to Battle Immune System from Afar
Perelman School of Medicine at the University of Pennsylvania
Checkpoint inhibitor therapies have made metastatic melanoma and other cancers a survivable condition for 20 to 30 percent of treated patients, but clinicians have had very limited ways of knowing which patients will respond. Researchers have uncovered a novel mechanism by which tumors suppress the immune system. Their findings also usher in the possibility that a straightforward blood test could predict and monitor cancer patients' response to immunotherapy.
No single test identifies all ROS1+ lung cancer patients
University of Colorado Cancer Center
University of Colorado Cancer Center study shows that common laboratory tests used to determine ROS1 status may return false-negative results, meaning that some patients who could benefit from ROS1-directed therapy may be slipping through the cracks.
FAU Scientist Receives $708,044 from Florida Department of Health for Cancer Metastasis Research
Florida Atlantic University
A leading scientist has been working to identify what contributes to the ability of tumor cells to move through the body and find other places to "set up shop." He has identified a number of enzymes that he believes are responsible for this process and is working to develop novel compounds to slow down this spreading aspect of cancer.
Johns Hopkins Kimmel Cancer Center Researchers Using Big Data to Predict Immunotherapy Responses
Johns Hopkins Medicine
In the age of Big Data, cancer researchers are discovering new ways to monitor the effectiveness of immunotherapy treatments.
Blue-light technology improves identification of bladder cancer
UT Southwestern Medical Center
Blue-light cystoscopy has previously been available at some institutions, including UT Southwestern, for use in the operating room, but it wasn't available in a flexible scope until now.
Taking a Pill Can Effectively Treat Brutal Lung Disease
Cincinnati Children's Hospital Medical Center
Researchers report in Nature Communications they figured out why air sacs in the lungs clog up with a thick substance called surfactant in a brutal disease called Pulmonary Alveolar Proteinosis (PAP), and they show taking cholesterol-busting pills called statins can effectively treat the disease.
First In-Human Clinical Trial Targeting CD4 Protein for Aggressive T-cell Leukemia and Lymphoma to be Launched
Stony Brook University
Stony Brook University, iCell Gene Therapeutics and University of Louisville collaborate to offer a new CAR T immunotherapy to treat patients.
Observing the Mechanism of Metastasis for the First Time
American Institute of Physics (AIP)
Metastasis is a leading contributor to many deaths related to cancer, but the exact mechanisms for how broken cellular function appears in cells far removed from a cancer's primary tumor remain an area of ongoing research. Scientists at the University of Minnesota Twin Cities confirmed a link between healthy-tumor hybrid cells and metastatic tumors for the first time in live animals. In APL Bioengineering, they discuss how they studied the distinct, heterogenous gene expression profiles found in human hybrid cells and how hybrid cells spontaneously occur in mouse models.
Smart Wristband With Wireless Link to Smartphones Could Monitor Health, Environmental Exposures
Rutgers University-New Brunswick
Rutgers University-New Brunswick engineers have created a smart wristband with a wireless connection to smartphones that will enable a new wave of personal health and environmental monitoring devices. Their technology, which could be added to watches and other wearable devices that monitor heart rates and physical activity, is detailed in a study published online in Microsystems & Nanoengineering.
Liquid Biopsy Could Ease the Way to Immunotherapy for Lung Cancer
UC Davis Comprehensive Cancer Center
Researchers at UC Davis, Genentech and Foundation Medicine are the first to show that a blood-based test to assess tumor mutational burden (TMB) accurately identifies non-small cell lung cancer (NSCLC) patients who could benefit from immunotherapies called checkpoint inhibitors. The blood test offers a much less invasive and more repeatable alternative to tissue testing. The study was published online today in Nature Medicine.
JNCCN--Journal of the National Comprehensive Cancer Network Strengthens Editorial Focus on Original, Impactful Research into Cancer Care Delivery
National Comprehensive Cancer Network(r) (NCCN(r))
JNCCN--Journal of the National Comprehensive Cancer Network introduces new Executive Editorial Board, reaches new heights for readership and impact rating thanks to expanding content, including new studies, panel insights, and NCCN Guidelines(r)
Tobacco Is Marketed More Heavily in Milwaukee's Minority Neighborhoods, Study Finds
University of Wisconsin-Milwaukee
Tobacco products in Milwaukee are more aggressively marketed in stores in African-American and Latino neighborhoods than in white ones, according to a study led by a public health researcher at the University of Wisconsin-Milwaukee.
Lung Cancer Screening Guidelines Inadequate for High-Risk Minorities
University of Illinois at Chicago
Data from a Chicago-based lung cancer screening program provides evidence that national lung cancer screening guidelines may be insufficient for individuals in underrepresented communities.
Role of Cell Group Behavior in Cancer Target of $1.9 Million Award
Washington University in St. Louis
Researchers have thought that cancer begins when a single cell goes rogue in the body, then begins to grow and multiply. Now, they are investigating evidence of more damage when a group of cells breaks off from a colony and more follow, leading to large-scale metastasis.
Women's Heart Fund Raises Over $140,000 in Support of the Center for Survivorship and Wellness Care at Jersey Shore University Medical Center's HOPE Tower
Hackensack Meridian Health
The Women's Heart Fund raised over $140,000 in support of the Center for Survivorship and Wellness Care at Hackensack Meridian Health Jersey Shore University Medical Center's HOPE Tower last month. More than 220 people came out to the Bay Head Yacht Club in Bay Head, New Jersey on June 1 in support of the center's comprehensive, and compassionate, holistic cancer care services.
Dana-Farber Launches Chinese-Language Website
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute launches a new Chinese-language website.
$100K Grant Fuels Research Efforts into Rare T-Cell Cancer
Rutgers Cancer Institute of New Jersey
A one-year, $100,000 grant awarded to a Rutgers Cancer Institute of New Jersey researcher from the Leukemia Research Foundation will support exploration into an aggressive blood cancer that impacts both children and adults - T-cell acute lymphoblastic leukemia (T-ALL).
Fred Hutch Tip Sheet: Acupuncture for Breast Cancer Patients; Nanoparticles Pave the Way for CAR T-cell Immunotherapy in Solid Tumors; Endometriosis and Childhood Abuse
Fred Hutchinson Cancer Research Center
This month's medical tip sheet from Fred Hutchinson Cancer Research Center includes stories about acupuncture for breast cancer patients, nanoparticles that pave the way for CAR T-cell immunotherapy in solid tumors and the link between childhood abuse and endometriosis later on in life. Also included is information on several awards and recognitions.
Scientists Identify New Mechanisms Underlying Pediatric Kidney Cancer
UT Southwestern Medical Center
Connecting two previously unrelated insights about the formation of pediatric kidney cancer, researchers at UT Southwestern Medical Center have uncovered the means by which the cancer continues to grow, providing potential targets for more effective treatments in the future.
Microscopic Imaging Pierces the "Black Box" of Cancer Bone Metastasis
University of Texas M. D. Anderson Cancer Center
Scientists at The University of Texas MD Anderson Cancer Center have engineered a system allowing microscopic monitoring and imaging of cancer that has spread to the bone in mice so they can better understand and develop treatment for bone metastasis in humans.
After 60 Years, Scientists Uncover How Thalidomide Produced Birth Defects
Dana-Farber Cancer Institute
More than 60 years after the drug thalidomide caused birth defects in thousands of children whose mothers took the drug while pregnant, scientists at Dana-Farber Cancer Institute have solved a mystery that has lingered ever since the dangers of the drug first became apparent: how did the drug produce such severe fetal harm?
Financial Checkup Should Be Part of Health Screenings for Childhood Cancer Survivors
St. Jude Children's Research Hospital
Adult survivors of childhood cancer should be screened for financial problems that might cause them to delay or skip medical care or to suffer psychological distress. The recommendation from St. Jude Children's Research Hospital researchers followed an analysis that found 65 percent of survivors reported financial challenges related to their childhood cancer diagnoses. More than half of survivors (51.1 percent) indicated they worried about paying for care, and 33 percent said finances kept them from seeking medical care.
Forum of International Respiratory Societies Commemorates and Supports Those Impacted by Lung Cancer
American Thoracic Society (ATS)
On World Lung Cancer Day, the American Thoracic Society, alongside members of the Forum of International Respiratory Societies (FIRS) commemorate and support those impacted by lung cancer. FIRS continues to support the grassroots efforts of the lung cancer community to raise awareness about lung cancer and its global impact, creating an educational movement around the world of understanding about lung cancer risks as well as the importance of early treatment.
Palliative Care: Another Level of Support in the Cancer Journey
Rutgers Cancer Institute of New Jersey
With word this week that former PGA Tour golfer Jarrod Lyle is transitioning from treatment for acute myeloid leukemia to palliative care, one might wonder what that form of care entails. A Rutgers Cancer Institute of New Jersey expert shares more about that part of the cancer journey.
The Surge in Throat Cancer, Especially in Men
UC Davis Comprehensive Cancer Center
Humanpapilloma virus (HPV) is now the leading cause of certain types of throat cancer. Dr. Michael Moore, director of head and neck surgery at UC Davis and an HPV-related cancer expert, answers some tough questions about the trend and what can be done about it.
$250K Grant Awarded to Rutgers Cancer Institute of New Jersey Researchers
Rutgers Cancer Institute of New Jersey
Rutgers researchers will benefit from a $250,000 grant from the Gillson Longenbaugh Foundation to help expand the team's work on neural stem cell interactions and developing antibody therapeutics for cancer treatment.
Turning Off Protein Could Boost Immunotherapy Effectiveness on Cancer Tumors
Johns Hopkins Medicine
Researchers at the Bloomberg~Kimmel Institute for Cancer Immunotherapy in the Johns Hopkins Kimmel Cancer Center discovered inhibiting a previously known protein could reduce tumor burdens and enhance the effectiveness of immunotherapy treatments.
Therapy for Rare Cancers Receives FDA Approval Following Trials at Penn's Abramson Cancer
Perelman School of Medicine at the University of Pennsylvania
The U.S. Food and Drug Administration (FDA) has approved the first ever non-surgical treatment for the rare neuroendocrine cancers pheochromocytoma and paraganglioma. The approval was based on a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania and was granted to Progenics Pharmaceuticals for AZEDRA (iobenguane I131).
Research on Mutation 'Hotspots' in DNA Could Lead to New Insights on Cancer Risks
Indiana University
New research from Indiana University has identified "hotspots" in DNA where the risk for genetic mutations from errors during cellular replication is significantly elevated. The results are significant since DNA errors play a significant role in many types of cancer.
Rogel Cancer Center awarded $33.4M from NCI
Michigan Medicine - University of Michigan
The National Cancer Institute has awarded the University of Michigan Rogel Cancer Center a grant worth $33.4 million over five years. At the same time, the center's designation as a "comprehensive cancer center" was renewed.
Bayshore Medical Center Launches Y-90 Radioembolization Outpatient Tumor Treatment
Hackensack Meridian Health
Hackensack Meridian Health Bayshore Medical Center now offers Y-90 radioembolization, an advanced and minimally invasive method to treat liver tumors without surgery. This procedure is used to treat patients who are not surgical candidates, but who have primary liver cancer or metastatic colon cancer. By directly targeting the tumor, Y-90 radioembolization reduces radiation damage to the healthy tissues surrounding tumors.
Ivosidenib earns FDA approval against IDH1+ acute myeloid leukemia
University of Colorado Cancer Center
Clinical trials at CU Cancer Center and elsewhere result in FDA approval of the drug ivosidenib for the treatment of adult patients with IDH1+ AML.
Software Framework Designed to Accelerate Drug Discovery Wins IEEE International Scalable Computing Challenge
Brookhaven National Laboratory
Designing a new pharmaceutical drug takes years of research, and now chemists and computational and computer scientists have developed a software framework that could help expedite this process by supporting accurate and rapid calculations of how strongly drug compounds bind to target molecules.
WVU Researchers Working to Stop Cancer-Growth Protein
West Virginia University
What do one in five breast cancers have in common? Large amounts of a protein called HER2 (or human epidermal growth factor receptor 2). "Every healthy cell produces a normal amount of HER2, but HER2 is produced 10 to 20 times more in a cancer cell," said Yehenew Agazie, an associate professor of biochemistry at the West Virginia University School of Medicine.
Scientists Discover a Dynamic Cellular Defense Against Breast Cancer Invasion
Johns Hopkins Medicine
Johns Hopkins researchers report they have demonstrated in mouse tissue grown in the lab that the cell layer surrounding breast milk ducts reaches out to grab stray cancer cells to keep them from spreading through the body. The findings reveal that this cell layer, called the myoepithelium, is not a stationary barrier to cancer invasion, as scientists previously thought, but an active defense against breast cancer metastasis.
What Is Important to Patients Undergoing Colorectal Surgery?
Diseases of the Colon and Rectum Journal
What do patients really want? These are Important questions that doctors at the University of Vermont have tried to answer. In the August issue of Diseases of the Colon & Rectum, Dr. Wrenn and his colleagues surveyed 167 patients who had undergone a colorectal resection between 2009 and 2015.
Switching Sides: The Betrayal of an Anti-Cancer Gene
Weizmann Institute of Science
Continuing his groundbreaking p53 studies, the Weizmann Institute of Science's Prof. Moshe Oren has shown how cancer cells within the tumor microenvironment - in particular, within the fibroblasts - can "brainwash" the p53 gene into helping cancer spread, rather than fighting it.
Combined Approach Offers Hope to Lung Cancer Patients Who Become Resistant to Drugs
Weizmann Institute of Science
Drug resistance is an all-too-common occurrence in cancer treatment. Now, working with physicians at Chaim Sheba Medical Center, the Weizmann Institute of Science's Prof. Yossi Yarden has identified a three-drug combo that fends off drug resistance in lung cancer. This is particularly promising, as two of the medications are already in use.
Dr. Benjamin Movsas Elected Education Council Vice-Chair of ASTRO's Board of Directors
Henry Ford Health System
Benjamin Movsas, M.D., FASTRO, chair of the Department of Radiation Oncology at Henry Ford Cancer Institute, has been elected to serve as Education Council Vice-chair on the American Society for Radiation Oncology Board of Directors.
Organ Transplant Patients Have Increased Skin Cancer Risk
American Academy of Dermatology
While people of any skin tone can develop skin cancer, specific risk factors in organ transplant patients may vary based on their race.
People With Skin of Color Face Unique Dermatologic Concerns
American Academy of Dermatology
A board-certified dermatologist can evaluate patients' conditions and provide them with the best possible treatment.
Early Detection Essential for Nail Melanoma
American Academy of Dermatology
Patient Karolina Jasko discusses her experience with nail melanoma, which is often overlooked and diagnosed late, resulting in a poor prognosis.
Leaders in radiation oncology awarded ASTRO Fellow designation
American Society for Radiation Oncology (ASTRO)
The American Society for Radiation Oncology (ASTRO) has selected 35 distinguished members to receive the ASTRO Fellow (FASTRO) designation. The 2018 class of Fellows will be recognized during ASTRO's 60th Annual Meeting, to be held October 21-24 in San Antonio.
Dr. Indrin J. Chetty named Fellow of the American Society for Radiation Oncology
Henry Ford Health System
Indrin J. Chetty, Ph.D., has been selected to be a Fellow of the American Society for Radiation Oncology (ASTRO).
Tobacco Regulation Advocates Get Support from Medical Professional Organizations in Court Filing
American Thoracic Society (ATS)
The American Thoracic Society led 10 medical professional organizations in filing an amicus brief last week regarding the FDA's failure to apply pre-market review to new tobacco products. The brief was submitted in support of the American Academy of Pediatrics and its co-plaintiffs and outlines the compelling data indicating that the FDA's failure to act harms children.
Artwork May Help Improve Patients' Perceptions of Their Hospital Experience
Penn State College of Medicine
Patients' perceptions of the hospital they're being treated in may be improved by the type of artwork hanging in hospital rooms, according to Penn State College of Medicine researchers.
Fitness Trackers Prove Helpful in Monitoring Cancer Patients
Cedars-Sinai
Fitness trackers can be valuable tools for assessing the quality of life and daily functioning of cancer patients during treatment, a new study has found. The trackers, also known as wearable activity monitors, include commercial devices worn on the wrist that log a wearer's step counts, stairs climbed, calories, heart rate and sleep.
Jersey Shore University Medical Center Earns Dual Awards from The Joint Commission for Lung and Esophageal Cancer Programs
Hackensack Meridian Health
Hospital holds status as the only currently certified organization for esophageal cancer in the country, and the only medical center in NJ with lung cancer certification.
Breast Cancer Radiation Treatment Reduced to a Single Dose
UT Southwestern Medical Center
Marilyn Gibson, 81, is part of a UT Southwestern Medical Center clinical trial testing a one-time, high-dose and highly focused radiation treatment called stereotactic radiotherapy for early-stage breast cancer.
Enabling Technology in Cell-Based Therapies: Scale-Up, Scale-Out or Program In-Place
SLAS (Society for Laboratory Automation and Screening)
Technologies that are reducing costs and changing the ways in which researchers and clinicians process and use therapeutic cells are showcased in the August 2018 special issue of SLAS Technology.
New Study in JNCCN Calls for Continued Aggressive Treatment for Breast Cancer in Women Under 40
National Comprehensive Cancer Network(r) (NCCN(r))
New Study in JNCCN focuses on women under 40 with breast cancer finds that young women who are treated with chemotherapy for breast cancer but have residual tumor in either the breast or lymph nodes have higher chances of recurrence compared to those with no evidence of any residual invasive tumor (pathologic complete response).
Antipsychotics Prove Effective in Killing Drug-Resistant Cancer Cells
Penn State Health Milton S. Hershey Medical Center
Two current drugs used to treat psychosis and depression showed anti-cancer activity in mice by blocking the movement of cholesterol within drug-resistant cancer cells, according to Penn State Cancer Institute researchers.
Curing Breast Cancer but at What Cost? Patients Report Heavy Financial Toll
Michigan Medicine - University of Michigan
A new study led by researchers at the University of Michigan Rogel Cancer Center finds many breast cancer patients are concerned about the financial impact of their diagnosis and treatment, and that they feel their doctor's offices are not helping with these concerns.
Low/No Calorie Soft Drinks Improve Outcomes in Advanced Colon Cancer Patients
Yale Cancer Center
Drinking artificially-sweetened beverages is associated with a significantly lower risk of colon cancer recurrence and cancer death, a team of investigators led by a Yale Cancer Center scientist has found. The study was published today in the journal The Public Library of Science One.
Discovery of Kidney Cancer Driver Could Lead to New Treatment Strategy
University of North Carolina Health Care System
In a study published in the journal Science, researchers suggest that ZHX2 is a potential new therapeutic target for clear cell renal cell carcinoma, which is the most common type of kidney cancer.
Replacing Conventional Cancer Treatment with Complementary Medicine Decreases Patient Survival
Yale Cancer Center
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from Yale Cancer Center and the Cancer Outcomes, Public Policy and Effectiveness Research Center (COPPER) at Yale School of Medicine. The findings were reported today online in JAMA Oncology.
Triple-Threat
University of Kansas Cancer Center
Triple-negative breast cancer expert Dr. Priyanka Sharma discusses latest research and clinical trial efforts.
Researchers Solve Mystery of How ALL Enters the Central Nervous System
Duke Health
A research team led by Duke Cancer Institute scientists has found that this blood cancer infiltrates the central nervous system not by breaching the blood-brain barrier, but by evading the barrier altogether.
Cancer Patients May Experience Delayed Skin Effects of Anti-PD-1 Therapy
Perelman School of Medicine at the University of Pennsylvania
Cancer patients receiving anti-PD-1 therapies who develop lesions, eczema, psoriasis, or other forms of auto-immune diseases affecting the skin may experience those adverse reactions on a delay - sometimes even after treatment has concluded.
$26.5M Grant Helps Investigators 'RESPOND' to Prostate Cancer
Rutgers Cancer Institute of New Jersey
Rutgers Cancer Institute of New Jersey, the NJ State Cancer Registry and the NJ Department of Health are collaborating on a $26.5 million study examining African-American men and prostate cancer. The 'RESPOND' study is being led by the Keck School of Medicine at USC.
Dr. Benjamin Movsas Elected President of the Society of Chairs of Academic Radiation Oncology Programs
Henry Ford Health System
Benjamin Movsas, M.D., Chair of the Department of Radiation Oncology at the Henry Ford Cancer Institute, has been named President of the Society of Chairs of Academic Radiation Oncology Programs (SCAROP).
$26.5 Million Grant to Fund First Large-Scale Study of African-American Men with Prostate Cancer
Johns Hopkins Medicine
Johns Hopkins Kimmel Cancer Center will participate in a $26.5 million effort to conduct the first large-scale, multi-institutional study on African-American men with prostate cancer to better understand why they are at higher risk for developing more aggressive forms of the disease and why they are more likely to die from it.
$26.5 Million Grant to Fund First Large-Scale Study on African-American Men with Prostate Cancer
Keck Medicine of USC
The Keck School of Medicine of USC is leading a $26.5 million effort to conduct the first large-scale, multi-institutional study on African-American men with prostate cancer.
By Sending Tests in the Mail, Researchers Boost Colorectal Cancer Screening
University of North Carolina Health Care System
Researchers with UNC Lineberger's Carolina Cancer Screening Initiative, in collaboration with the Mecklenburg County Health Department in Charlotte, examined the impact of mailing tests to more than 2,100 people insured by Medicaid who were not up-to-date with colorectal cancer screening.
Overcoming a Major Barrier to Developing Liquid Biopsies
Michigan Medicine - University of Michigan
An international consortium of labs tested nine different methods for RNA sequencing to understand and standardize the best methods for sequencing small RNAs. The goal was to create a process that could be reproduced from one lab to the next to further the field of liquid biopsies.